Ajanta Pharma Limited (BOM:532331)
India · Delayed Price · Currency is INR 3,640.35
-25.30 (-0.69%)
At close: Aug 21, 2026
Ajanta Pharma Financials Overview
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Revenue Revenue Growth | 57,762 | 54,529 | 46,481 | 42,087 | 37,426 | 33,410 |
Revenue Growth | 20.19% | 17.31% | 10.44% | 12.45% | 12.02% | 15.62% |
Gross Profit Gross Profit Growth | 44,603 | 41,889 | 35,052 | 30,877 | 26,324 | 24,570 |
Operating Income Operating Income Growth | 14,011 | 13,266 | 11,285 | 10,457 | 6,798 | 8,079 |
Net Income Net Income Growth | 11,349 | 10,560 | 9,204 | 8,162 | 5,880 | 7,127 |
Earnings Per Share EPS Growth | 90.81 | 84.51 | 73.53 | 64.77 | 45.89 | 54.96 |
EPS Growth | 22.02% | 14.94% | 13.52% | 41.14% | -16.50% | 9.79% |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Investments Cash & Investments Growth | 6,631 | 6,631 | 6,138 | 4,595 | 8,401 | 3,282 |
Total Debt Total Debt Growth | 2,659 | 2,659 | 509.2 | 368.4 | 394.7 | 345.2 |
Net Cash (Debt) Net Cash Growth | 3,972 | 3,972 | 5,629 | 4,227 | 8,006 | 2,937 |
Net Cash Growth | -29.44% | -29.44% | 33.17% | -47.20% | 172.60% | -13.73% |
Net Cash Per Share Net Cash Per Share Growth | 31.78 | 31.79 | 44.97 | 33.55 | 62.49 | 22.65 |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Cash Flow Operating Cash Flow Growth | - | 5,292 | 11,572 | 7,851 | 7,921 | 5,617 |
Capital Expenditures CapEx Growth | - | -3,652 | -3,179 | -1,524 | -1,745 | -1,488 |
Free Cash Flow Free Cash Flow Growth | - | 1,640 | 8,393 | 6,327 | 6,176 | 4,129 |
Free Cash Flow Growth | - | -80.46% | 32.66% | 2.44% | 49.59% | 2.02% |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Gross Margin | 77.22% | 76.82% | 75.41% | 73.36% | 70.34% | 73.54% |
Operating Margin | 24.26% | 24.33% | 24.28% | 24.84% | 18.16% | 24.18% |
Pretax Margin | 25.85% | 25.26% | 25.58% | 26.47% | 19.91% | 27.22% |
Profit Margin | 19.65% | 19.37% | 19.80% | 19.39% | 15.71% | 21.33% |
FCF Margin | - | 3.01% | 18.06% | 15.03% | 16.50% | 12.36% |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 22, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Dividend Per Share Dividend Per Share Growth | 60.000 | 28.000 | 28.000 | 36.000 | 7.000 | 6.333 |
Dividend Per Share Growth | 0% | 0% | -22.22% | 414.29% | 10.53% | 0% |
Dividend Yield | 1.65% | 1.01% | 1.09% | 1.66% | 0.61% | 0.56% |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 22, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 40.07 | 33.17 | 35.59 | 34.42 | 26.34 | 21.70 |
P/FCF Ratio | 277.23 | 213.57 | 39.03 | 44.40 | 25.08 | 37.46 |
PS Ratio | 7.87 | 6.43 | 7.05 | 6.67 | 4.14 | 4.63 |